language
Language
Englishchevron_right
attach_money
Currency
$USDchevron_right
dark_mode
Dark Mode
policy
Privacy Policy
gavel
Terms of Service
TMCITMCI

$1.87

-0.36
arrow_drop_down16.14%
Current Market·update16 Apr 2026 20:00

$1.86

-0.01
arrow_drop_down0.53%
Pre-market·update17 Apr 2026 08:00
Day's Range
1.835-2.2701
52-week Range
1.17-7.78

Chart

Loading chart...

Performance

Key Stats

Next Earnings Date2026-02-27
Next Earnings TimeBefore Market Open
Volume825.87K
Average Volume 30d889.84K

AI TMCI Summary

Powered by LiveAI
💰
-7.4
Valuation (P/E Ratio)
Below industry average
📈
-0.85
EPS Growth (YoY)
Negative earnings growth
Show More 🔒

AI Scoreboard

Powered by LiveAI
🔒

Overall Analysis

Buy
65

Treace Medical Concepts shows potential for growth driven by its innovative bunion correction system, but faces profitability challenges and a volatile technical outlook. Investors should monitor upcoming earnings and market sentiment.

Neutral

Thematic

60

Treace Medical Concepts operates in the growing medical technology sector, focusing on orthopedic solutions. While its specialized products address specific medical needs, broader thematic tailwinds are not as pronounced as in other tech sectors.

Neutral

Fundamental

65

Treace Medical Concepts exhibits revenue growth, but is currently unprofitable and faces significant operating expenses. Its balance sheet shows manageable debt but declining cash reserves over recent years.

Neutral

Technical

68

The stock is trading below key moving averages, indicating a bearish short-to-medium term trend, though some oscillators suggest a potential for a bounce. Support levels need to be monitored.

FactorScore
Aging Population & Healthcare Demand75
Medical Device Innovation80
Regulatory Landscape (Medical Devices)50
Competition in Orthopedics60
Shift to Minimally Invasive Procedures70
FactorScore
Valuation60
Profitability20
Growth70
Balance Sheet Health65
Cash Flow30
FactorScore
Trend Analysis30
Momentum50
Volume Confirmation60
Support & Resistance75
MACD40

AI Investing Checklist

Powered by LiveAI
thumb_up

Bullish Points (5)

Financial Health & Liquidity chevron_right

Positive Cash Flow from Operations

The company has a positive operating cash flow of $4.198 million in Q1 2025, indicating its core business operations are generating cash.

Earnings Performance chevron_right

Improving EPS Quarter-over-Quarter

EPS has improved from -0.36 in Q1 2024 to -0.30 in Q2 2025, showing a positive trend in earnings.

Show More 🔒
thumb_down

Bearish Points (8)

Earnings Performance chevron_right

Consistent Net Losses

The company has reported net losses for all analyzed periods, with net income in 2024Q4 being -$0.501 million and a TTM net income of -$31.783 million.

Financial Health & Debt chevron_right

Significant Debt Load

The company has a total debt of $69.653 million in 2024Q4 and total liabilities of $104.202 million, with a negative EPS of -$0.85 TTM.

Show More 🔒

Calendar

August 2025

6

Next Earnings Date

EPS Est.
Revenue Est.

H: $-0.26

A: $-0.29

L: $-0.31

H: 47.14M

A: 47.08M

L: 47.00M

Profile

Websitetreace.com
Employees (FY)477
ISINUS89455T1097
FIGI-

Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to correct three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible correction of metatarsus adductus deformities and osteoarthritis of the midfoot. It serves physicians, surgeons, ambulatory surgery centers and hospitals related to the surgical management of bunion and related midfoot deformities. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.

Seasonals

2025
2024
2023
2022
2021

Price Target

10.02 USD

The 39 analysts offering 1 year price forecasts for TMCI have a max estimate of 14.50 and a min estimate of 8.00.

Debt Level and Coverage

Debt
Free cash flow
Cash & equivalents

Financial Position Analysis

Assets
Liabilities

Ownership

Free Float shares
47.1M (74.90%)
Closely held shares
15.8M (25.10%)
62.9M
Free Float shares
47.1M (74.90%)
Closely held shares
15.8M (25.10%)

Capital Structure

Market cap
364.22M
Debt
69.65M
Minority interest
0.00
Cash & equivalents
11.35M
Enterprise value
422.52M

Valuation - Summary

Market Cap
368M
Net income
-31.8M(-8.64%)
Revenue
166M(45.21%)
368M
Market Cap
368M
Net income
-31.8M(-8.64%)
Revenue
166M(45.21%)
Price to earning ratio (P/E)-11.60x
Price to sales ratio (P/S)2.20x

Valuation - Ratios

P/E
P/S

Revenue to Profit Conversion

Revenue
209.36M
COGS
41.09M
Gross Profit
168.26M
OpEx
223.95M
Operating Income
-55.69M
Other & Taxes
55K
Net Income
-55.74M

Balance Sheet

Total assets
Total liabilities
Liabilities to assets %

Income Statement

Revenue
Net Income
Net Margin

Cash Flow

Operating Cash Flow
Investing Cash Flow
Financing Cash Flow
Show More 🔒